A large international study led by Duke researchers found that the diabetes drug empagliflozin slowed the time to first hospitalization for heart failure and reduced the total number of subsequent heart failure hospitalizations in patients after they had suffered acute myocardial infarction.

Allan D. Kirk, MD, PhD, FACS, has been awarded the 2024 Flance-Karl Award by the American Surgical Association (ASA). The Flance-Karl Award recognizes surgeons in the U.S. who have made seminal contributions in basic laboratory research which has application to clinical surgery.

A new mathematical model offers hope for better prediction and treatment of Alzheimer’s disease. 

Dr. Klotman shares news about new funding, Match Day, Distinguished Professorships and more.

Scientists at Duke University School of Medicine have long probed the mysteries of RNA, with an eye to harnessing its power for new and better therapies for cancer, diabetes, heart disease and more.

Duke Health is part of a multi-institution research team receiving funding from the federal Advanced Research Projects Agency for Health (ARPA-H) to develop an osteoarthritis treatment that regenerates joints.

Four students at the Duke University School of Medicine have been named to the 2023-24 class of the North Carolina Albert Schwe

Palliative care -- relief from symptoms -- significantly improves a patient’s quality of life and eases fatigue, depression and post-traumatic stress symptoms while they are hospitalized for bone marrow transplant.

Bob Keegan is empowering a pioneering Duke Health team with a transformational gift to kick-start the new Duke Heart Precision and Innovation Collaboratory.

Sneha Mantri, MD, a neurologist and one of five new Macy Faculty Scholars, will use the opportunity to expand Moral Movements in Medicine to offer empathy training to health professionals students.